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 1 
ABSTRACT 34 
Type 2 diabetes is a chronic metabolic disorder where failure to maintain normal glucose 35 
homeostasis is associated with, and exacerbated by, obesity and the concomitant elevated 36 
free fatty acid concentrations typically found in these patients. Hyperglycaemia and 37 
hyperlipidaemia together contribute to a decline in insulin-producing β-cell mass through 38 
activation of the transcription factors NF-κB and STAT1. There are however a large 39 
number of molecules potentially able to modulate NF-κB and STAT1 activity, and the 40 
mechanism(s) by which glucolipotoxicity initially induces NF-κB and STAT1 activation 41 
is currently poorly defined. Using high density microarray analysis of the β-cell 42 
transcritptome we have identified those genes and proteins most sensitive to glucose and 43 
fatty acid environment. Our data shows that of those potentially able to activate STAT1 44 
or NF-κB pathways, TNFR5 is the most highly upregulated by glucolipotoxicity. 45 
Importantly our data also shows that the physiological ligand for TNFR5, CD40L, elicits  46 
NF-κB activity in β-cells, whereas selective knock-down of TNFR5 ameliorates 47 
glucolipotoxic induction of STAT1 expression and NF-κB activity. This data indicates 48 
for the first time that TNFR5 signalling plays a major role in triggering glucolipotoxic 49 
islet cell death. 50 
 51 
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INTRODUCTION 57 
In 2011 it was estimated that there were 347 million people worldwide living with 58 
diabetes (1). Moreover the incidence of diabetes continues to grow at an alarming rate, 59 
with the figure in 2030 projected to be more than double that which was reported in  2000 60 
(2). There are a limited number of options  to treat type 2 diabetes (T2D), and 61 
furthermore oral and injectable medications often become less effective over time. Thus 62 
there is an urgent need to better understand the causes of diabetes, and to identify new 63 
targets for the development of novel treatment strategies.  64 
 65 
Hyperglycaemia and hyperlipidaemia together contribute to the gradual loss of β-cell 66 
function that has been observed in patients with T2D. In addition to the failure of 67 
compensatory hypersecretion to overcome insulin resistance, reduction in β-cell mass 68 
through increased apoptosis is a key component of T2D (3,4). Increased metabolic stress 69 
results in activation of the transcription factors NF-κB (5,6) and STAT1 (7). These then 70 
trigger the synthesis of a number of β-cell proteins, including the cytokine IL-1β (8). This 71 
is then released from the cell, whereupon it is able to bind the β-cell surface IL-1 receptor 72 
and amplify both NF-κB activation and the subsequent cytokine response that is driven 73 
through activation of NLRP3 inflammasomes (5). In addition inflammasome activation 74 
can also lead to caspase-1-mediated cell death through a process termed pyroptosis, 75 
which both fragments DNA and leads to pore formation in the plasma membrane (9).  76 
 77 
As well as these IL-1β-mediated cytokine response pathways, a number of chemokines 78 
are also synthesized and released by β-cells following glucolipotoxic activation of NF-κB 79 
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(5). These serve to attract circulating immune cells, which then infiltrate the pancreas and 80 
are specifically drawn toward β-cells (10,11). Here these immune cells release their own 81 
cocktail of cytokines. Along with glucolipotoxicity-induced β-cell IL-1β release, this 82 
localised toxic milieu effectively destroys β-cells.  83 
 84 
Whilst we know many of the events resulting from NF-κB activation, the initial trigger of 85 
glucolipotoxic NF-κB activation remains poorly defined. Endoplasmic reticulum (ER) 86 
stress is one mechanism that has been proposed to initiate this response (12). However as 87 
ER stress is typically induced by an increase in synthesis of client proteins this is more 88 
likely to occur in response to increased transcriptional activity and the resulting increase 89 
in protein synthesis and ER throughput. Hence ER stress is more likely to be a 90 
consequence rather than cause of increased transcriptional activity and /or islet 91 
inflammation. There are some exceptions, such as Wolfram Syndrome where there is a 92 
coding mutation in the protein wolframin that is thought to regulate ER Ca2+ flux and 93 
thereby ensure protein fidelity and the degradation of misfolded proteins (13). However, 94 
as this and similar genetic disorders are relatively rare they are unlikely to contribute to 95 
ER stress in the majority of people with T2D.  96 
 97 
Oxidative stress is another mechanism commonly championed as the initial driver of 98 
gluco-or lipotoxic NF-κB activation in β-cells. This is also questionable however, since 99 
reactive oxygen species (ROS) trigger a rapid spike in intracellular Ca2+ that results in 100 
transient exocytosis of insulin (14,15). Indeed, there is increasing evidence to suggest that 101 
reactive oxygen species are essential for normal β-cell function, including insulin 102 
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secretion (16). Furthermore, some anti-oxidants potently inhibit glucose-stimulated 103 
insulin secretion, not enhance it (17). This may help explain why levels of the H2O2-104 
inactivating enzymes glutathione peroxidase and catalase are particularly low in β-cells, 105 
when compared for example with expression level in the liver (18). This does not mean 106 
that β-cells are incapable of sustaining damage from excessive oxidative stress. However, 107 
given the routine high glycolytic throughput of β-cells and the general tolerance of β-108 
cells against levels of ROS that would be damaging to other cells, it would seem 109 
incongruous were glucolipotoxicity to exert a disproportionately damaging effect upon 110 
pancreatic function.     111 
 112 
In order to more accurately define the initial mechanisms triggering glucolipotoxicity-113 
induced β-cell dysfunction we used a combination of microarray expression profiling, 114 
independent quantitative PCR analysis, Western blotting, confocal microscopy, and NF-115 
κB activity assays to identify those genes and proteins whose expression is most sensitive 116 
to glucose and fatty acid environment. Our data indicates that of the genes most likely to 117 
be associated with cell death pathways TNFR5 (also known as CD40) is the most highly 118 
upregulated and is able to induce STAT1 and NF-κB activation. Importantly, this  pattern 119 
of upregulation was not restricted to rat insulinoma cells alone, but also isolated mouse 120 
islets from high fat-fed mice and human islets, indicating that this may represent a 121 
conserved cell death activation mechanism.  122 
 123 
 124 
 125 
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RESULTS 126 
In order to better understand the mechanisms by which chronic exposure to high glucose 127 
and fatty acids alters cellular function we incubated INS-1 rat pancreatic β-cell 128 
insulinoma cells for 72h in RPMI-1640 media and media supplemented with 28mM 129 
glucose, 200µM oleic acid, and 200µM palmitic acid. Total RNA was isolated and 130 
hybridized to Affymetrix rat microarray chips. Approximately 10% of INS-1 transcripts 131 
underwent a 2-fold or greater change in expression that was statistically significant 132 
(Appendix Table 1). This included genes linked to apoptosis and related signalling 133 
pathways, biological oxidation, nucleic acid processing and repair (Fig. 1). To better 134 
understand how altered function in these genes correlates with human disease we 135 
employed Metacore analysis algorithms (https://portal.genego.com) to identify the 25 136 
diseases most closely associated with our dataset. Table 1 indicates the degree of 137 
significance, along with enrichment expressed as the ratio of the number of genes that 138 
would be expected to be associated to each specific disease by chance (shown in green) 139 
compared to the number of the differentially expressed genes enriched in our dataset 140 
(shown in red).  141 
 142 
For molecules linked to inflammation and apoptosis we found changed expression in a 143 
number of tumour necrosis receptor (TNFR) superfamily members and associated factors. 144 
Of these TNFRSF5, the gene encoding TNFR5, was found to be the most highly 145 
upregulated with 2.23 fold expression (p<0.01) (Table 2). In order to validate these 146 
results we performed independent qRT-PCR analysis of TNFRSF5, as well as the genes 147 
encoding TNFR1 and TNFR6 (also known as Fas) which have previously been shown to 148 
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mediate cytokine-induced islet inflammation and apoptosis. Again we observed 149 
significant increase in TNFRSF5 expression (3.62 fold; p<0.01) induced by high glucose 150 
and fatty acid environment (Table 2). TNFRSF1A was also upregulated by greater than 2 151 
fold, but variable response meant that this was not deemed statistically significant in the 152 
samples examined. TNFRSF6 by contrast was only modestly upregulated, with this not 153 
found to be statistically significant in the PCR experiments. As a consequence we 154 
focused our investigation on TNFR5 for the remainder of this study. 155 
 156 
Although our data indicate significant upregulation in TNFRSF5 gene expression in β-157 
cells exposed to a glucolipotoxic environment, mRNA does not always equate to protein. 158 
Therefore we incubated INS-1 cells for 72h in RPMI-1640 supplemented with either 159 
28mM glucose, 200µM oleic acid, or 200µM palmitic acid, both individually and in 160 
combination, and immunoblotted with anti-TNFR5 polyclonal antibody. The combination 161 
of glucose and fatty acids induced the strongest (2-3 fold; p<0.01) upregulation in 162 
TNFR5 protein (Fig. 2a), although fatty acids or glucose alone also induced upregulation 163 
albeit by a more modest increase. This data is supported by immunofluorescence 164 
experiments (Fig. 2b), in which there was a strong increase in TNFR5 intensity (green) in 165 
INS-1 cells incubated for 72h in the presence of high glucose and fatty acids. Thus a 166 
parallel increase in protein levels assessed both by Western blot an immunofluorescence 167 
was detected under glucolipotoxic conditions. 168 
 169 
INS-1 tissue culture cells offer a consistent response to experimental manipulation, which 170 
makes them an ideal choice for microarray analysis where large numbers of repeat 171 
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experiments are costly. However as transformed β-cell lines are not always fully 172 
representative of primary β-cell biology it becomes important to determine whether these 173 
findings are indicative of whole animal physiology. Therefore C57Bl/6 mice were fed a 174 
high fat diet for 10 weeks, resulting in impaired glucose tolerance, diminished insulin 175 
secretion, and reduced islet size. Pancreas was removed and total RNA extracted from 176 
isolated islets. In line with our INS-1 cell data, qRT-PCR analysis of extracted RNA 177 
showed a 2-fold increase in TNFRSF5 expression in the high fat fed mice relative to lean 178 
controls (Fig. 2c). In order to determine whether our data was also reflective of human 179 
physiology we next isolated islets post-mortem from human donors. These islets were 180 
incubated for 24h in RPMI-1640 supplemented +/- 0.5mM palmitate, total RNA 181 
extracted and qRT-PCR performed. Despite the shorter incubation period we again 182 
observed statistically significant upregulation of TNFRSF5 (1.4 fold; p<0.05) (Fig. 2d), 183 
indicative of a similar pattern of upregulation of TNFRSF5 in rodent and human islets.  184 
 185 
In order to identify wider TNFR5 pathway interactions non-biased network analysis was 186 
performed using the MetaCore integrated knowledge database of pathways 187 
(https://portal.genego.com). The gene content from microarray analysis files was used as 188 
the input list for generation of biological networks using the Analyze network algorithm 189 
with default settings. This is a variant of the shortest paths algorithm with main 190 
parameters of 1. relative enrichment with the uploaded data, and 2. relative saturation of 191 
networks with canonical pathways. CD40L signalling through TNFR5 came out as the 192 
top ranked of all upregulated networks irrespective of cellular function. A further major 193 
finding from this analysis was the central involvement of JAK/STAT signalling pathways 194 
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(Fig. 3). As JAK/STAT signalling is often also linked to additional cytokine signalling 195 
through IFNγ-related pathways we were able to able to assess the likely validity of these 196 
predictions by going back to our original dataset and determining whether interferon-197 
related genes showed changed expression. Of the six genes that came through our 198 
bioinformatic filter with statistically significant data, all six were upregulated. 199 
Furthermore, upregulation of all six genes was further confirmed by independent PCR 200 
analysis and shown to be statistically significant (p<0.001, Appendix Table 2).  201 
 202 
In order to gain more detailed understanding of the contribution of TNFR5 in triggering 203 
glucolipotoxic STAT1 and NF-kB responses we selectively modulated TNFR5 204 
expression and activity and determined the resulting effect on STAT1 and NF-κB. INS-1 205 
cells were transfected with either scramble sequence or siRNA specifically directed 206 
against TNFR5, then incubated for a further 72h in media supplemented with or without 207 
28mM glucose, 200μM oleic acid, and 200μM palmitic acid. Whilst the scramble 208 
sequence had no effect upon TNFR5 expression, the selective oligonucleotide brought 209 
down expression of TNFR5 by 96.0 +/- 1.0% in cells cultured in standard RPMI-1640, 210 
and by 97.8 +/- 1.3% in cells cultured in RPMI-1640 supplemented high glucose and 211 
fatty acids (Fig. 4a). We then went on to determine STAT1 expression in these cells. 212 
Culturing cells for 72h in media supplemented with high glucose and fatty acids resulted 213 
in STAT1 expression more than doubling (Fig. 4b). However in cells where TNFR5 had 214 
been knocked down (siRNA lanes) STAT1 expression decreased by 61.0 +/- 4.0% in 215 
cells cultured in standard RPMI-1640 media (left panel), and by 54.6 +/- 2.9% in cells 216 
cultured in RPMI-1640 supplemented with high glucose and fatty acids (right panel). 217 
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 218 
We next investigated how glucolipotoxicity and TNFR5 activity affect NF-κB 219 
expression, localization and activity. Following 72h incubation in media supplemented 220 
with 28mM glucose and 200µM fatty acids we observed a 73.5 +/- 5.7% increase in NF-221 
κB expression (Fig. 5a). Similarly, 6h exposure of INS-1 cells to 1µg/ml CD40L (the 222 
physiological activator of TNFR5) resulted in increased translocation of the NF-κB p65 223 
subunit to the nucleus (Fig. 5b). Whilst this is consistent with NF-κB activation by 224 
TNFR5, we nonetheless sought to confirm this using a quantitative ELISA assay that we 225 
have previously used to determine NF-κB activity in nuclear extracts isolated from cells 226 
of patients with autoinflammatory fevers (19-21). Using this assay we were also able to 227 
compare NF-κB activity in β-cells treated with high glucose, TNFα, or CD40L. As can 228 
be seen (Fig. 5c) 72h incubation of INS-1 cells in 28mM glucose resulted in an increased 229 
level of NF-κB activity similar to that observed following 2h exposure of cells to 230 
100ng/ml of TNFα. However under low glucose conditions where TNFR5 expression is 231 
not upregulated beyond basal, 6h exposure to 1µg/ml CD40L nevertheless still succeeded 232 
in eliciting half-maximal induction of NF-κB activity.  233 
 234 
The above experiments detail how glucolipotoxicity influences TNFR5 expression and 235 
activity. They do not however tell us whether the increased NF-κB activation is 236 
dependent upon TNFR5, or is instead simply coincidental to increased TNFR5 expression 237 
and activity. In order to address this point we again knocked down TNFR5 expression, 238 
then measured NF-κB activity in mock-transfected cells, cells transfected with scramble 239 
sequence, and cells transfected with selective oligonucleotide. Although we were only 240 
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able to achieve a much more modest knock down of TNFR5 in this particular series of 241 
experiments (58.3 +/- 16.9%), this still significantly ablated NF-κB activity by 46.7 +/- 242 
8.2%. 243 
 244 
 245 
DISCUSSION 246 
Using an unbiased high density microarray screen we have been able to determine the 247 
effect of high glucose and fatty acid environment on thousands of genes simultaneously. 248 
Among the top 25 hits out data indicates the presence of disease association with both 249 
endocrine and metabolic disorders, which suggests the presence of pathways with known 250 
type 2 diabetes and obesity aetiology in man. Interestingly, the molecules differentially 251 
expressed in this study were also found to be important in other diseases. Of those 252 
diseases were a number of brain disorders. This may reflect the pancreas being a highly 253 
innervated organ that shares a number of molecular similarities with brain at the level of 254 
transcriptome and proteome, the roots to which likely lie in the fact that the pancreas 255 
contains ancestral precursors of both pancreatic and neural crest origin (22). The data also 256 
indicates changed expression of genes associated with pathways common to many forms 257 
of neoplasm. Epidemiologic evidence suggests that people with diabetes are at 258 
significantly higher risk for many forms of cancer (23). Furthermore several studies 259 
indicate an association between diabetes and risk of liver, pancreatic, endometrial, 260 
colon/rectum, breast, and bladder cancer. While common risk factors such as age, 261 
obesity, physical inactivity and smoking undoubtedly contribute to increased cancer risk 262 
in diabetic patients, hyperinsulinemia may also increase the likelihood of developing 263 
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cancer due to insulin being a growth factor with metabolic and mitogenic effects. Its 264 
action in malignant cells is also favoured by mechanisms acting at both the receptor and 265 
post-receptor level (24).  266 
 267 
In agreement with the data presented here, it has previously been shown that both human 268 
and murine pancreatic β-cells express functional TNFR5 (25,26). Our observation that 269 
exposure of β-cells to high levels of glucose and/or fatty acids results in a 2-4 fold 270 
increase in expression of TNFR5 may therefore have clinical implications. However, 271 
without ligand activation increased receptor expression is unlikely to have a significant 272 
deleterious impact on functional β-cell mass. The pro-apoptotic response to glucose and 273 
lipids is not restricted to islet cells alone though. Previous work has shown that Indian 274 
subjects with diabetes have approximately 3 times higher sCD40L levels in their plasma 275 
than individuals with normal glucose tolerance (27). The same study also found that 276 
plasma sCD40L levels were also elevated in people with impaired glucose tolerance, 277 
Metabolic Syndrome, and insulin resistance. Other researchers reported similar findings 278 
in a subsequent study in Europeans with type 2 diabetes (28). Interestingly, this latter 279 
publication also reported a significant decrease in platelet TNFR5 signalling following 280 
sustained reduction in HbA1c, indicating that the process may be reversible. A positive 281 
correlation between glycaemic control and sCD40L level has also recently been reported 282 
in patients with type 1 diabetes (29).      283 
 284 
Our predictive pathway analysis indicates the potential for TNFR5 to regulate a wide 285 
range of cellular functions, including those that direct the ultimate fate of the β-cell – 286 
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namely life and regeneration through cell proliferation (STAT5, MAP3K) and cell cycle 287 
(cyclins and associated kinases), or cell death (Bcl-2, Bcl-XL). At the heart of each of 288 
these pathways however lies NF-κB and/or STAT1. Therefore the combination of high 289 
sCD40L levels found in diabetes and the upregulated expression of functional β-cell 290 
receptor shown here suggests that TNFR5 signalling may be responsible for much of the 291 
glucolipotoxicty-induced NF-κB activity in humans. Furthermore, given that NF-κB (5,6) 292 
and STAT1 (7) activity are known to subsequently lead to islet cell death we hypothesise 293 
that TNFR5 signalling likely represents a major cause of islet cell death in people with 294 
poorly controlled glucose homeostasis and chronically elevated levels of glucose and 295 
fatty acids.  296 
 297 
As glucolipotoxic induction of both STAT1 and NF-κB expression and activity can be 298 
prevented by down-regulation of TNFR5 expression this has major potential therapeutic 299 
implications, not least as it might be possible to enhance islet cell survival through 300 
targeted disruption of TNFR5 pathways. Anti-TNFR5 strategies have previously been 301 
employed as a general immunosuppressant strategy following transplantation, and also to 302 
treat people suffering from lupus and several types of cancer. Intervention has not always 303 
met with success however, as there are a number of reports where anti-CD40L 304 
monoclonal antibodies have been shown to induce thromboembolic events (30-33). 305 
Importantly, these dangerous side-effects have not been observed when the receptor, 306 
rather than ligand, is targeted. Indeed there are now numerous highly promising clinical 307 
trials taking place involving different anti-TNFR5 monoclonal antibodies (34,35). Of 308 
these, those employing antagonistic anti-TNFR5 antibodies are of particular relevance to 309 
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our current study. Lucatumumab is one such example that has been found to be well 310 
tolerated (36), at least in moderate and intermediate strength doses (37). Importantly it 311 
has also been shown to prevent induction of NF-κB activity in multiple myeloma cells 312 
(38). This strategy would need to be modified for the treatment of diabetes though, as 313 
immune cell interactions with the Fc region of cell-bound lucatumumab could potentially 314 
lead to either opsonisation of β-cells or antibody-dependent cell cytotoxicity. Phage 315 
display technology may provide an alternative solution however, facilitating the 316 
generation of antibody fragments containing the key heavy and light chain antigen 317 
recognition sites, whilst lacking the Fc region of the full molecule. This is an area that 318 
clearly warrants future research.  319 
 320 
 321 
MATERIALS & METHODS 322 
 323 
Materials 324 
Antibodies were obtained from Santa Cruz Biotechnology Inc. (Dallas, TX, USA), Cell 325 
Signalling Technology (Beverly, MA, USA) and Li-Cor Bioscience (Lincoln, NE, USA). 326 
Unless otherwise stated, all other chemicals were purchased from Sigma Aldrich (St. 327 
Louis, MO, USA) or VWR International Ltd (Lutterworth, UK). 328 
 329 
Cell Culture and Islet isolation 330 
INS-1 β-cells was cultured in RPMI-1640 media supplemented where indicated with 331 
28mM glucose, 200µM oleic acid, or 200µM palmitic acid for 72 hours as detailed 332 
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previously (39). C57Bl/6 mice (Charles River, UK) were fed a high-fat (60% fat-58Y1; 333 
Test Diets, USA) or standard rodent diet for 10 weeks. Pancreas was surgically removed 334 
and digested in Hanks Buffered Salt Solution containing collagenase P (1mg/ml) and 335 
DNAse I (0.15mg/ml; both Roche Diagnostics, Burgess Hill, UK). All animal 336 
experiments were conducted in accordance with the UK Home Office Animals (Scientific 337 
Procedures) Act, 1986, with local ethical committee approval. Human islets were isolated 338 
from non-diabetic multiorgan donors as previously detailed (40), with approval of the 339 
local ethics committee and with written informed consent from family members. In both 340 
cases islets were hand-picked into RPMI-1640 and immediately lysed for RNA or protein 341 
experiments. 342 
 343 
Quantitative RT-PCR  344 
Cells were trypsinised, washed with cold PBS and lysed in RNAeasy QTL lysis buffer. 345 
Total RNA was prepared from lysed cells using RNeasy® kit according to manufacturers 346 
recommended procedures. (Qiagen). cDNA was generated from RNA using a standard 347 
RT kit (Promega, Madison, WI, USA). Real-time qPCR reactions were performed using 348 
Maxima SYBR Green/ROX qPCR Master Mix (Thermo) and the following primers:: rat 349 
CD40 forward primer GTCGGATTCTTCTCCAATG; rat CD40 reverse primer  350 
ACAGAGGGTATCAGTCTGAC; mouse CD40 forward primer 351 
TGGTCATTCCTGTCGTGATG; mouse CD40 reverse primer 352 
GGCTCTGTCTTGGCTCATCT. Human islet experiments were performed as previously 353 
described (41), with CD40 oligonucleotide obtained from assay-on-demand gene 354 
expression products (Applied Biosystems, Foster City, CA, USA). Target gene mRNA 355 
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was quantified and normalized for β-actin using an ABI7700 bioanalyzer (Applied 356 
Biosystems). Data was analysed using the ΔΔCT method. 357 
 358 
Affymetrix arrays  359 
Quality and integrity of extracted RNA was assessed using an Agilent Bioanalyser 2100. 360 
10 µg total RNA was converted into double-stranded cDNA using Superscript Reverse 361 
Transcriptase kit (Life Technologies Ltd, Paisley, UK) following manufacturer’s T7-(dT) 362 
-based recommendation. T7 RNA polymerase was then used to convert the cDNA to 363 
biotin labelled cRNA. cRNA generated with T7 polymerase was chemically fragmented, 364 
then hybridized overnight at 45 °C to Affymetrix® high density GeneChip® Rat Genome 365 
230 2.0 arrays, each containing 31,000 probe set, analyzing over 30,000 transcripts and 366 
variants from over 28,000 well-substantiated rat genes following Affymetrix Expression 367 
Analysis Technical Manual procedures. Chips were then washed and stained with 368 
streptavidin-phycoerythrin (SAPE). Signals were amplified by incubation with 369 
biotinylated anti-streptavidin antibody (Vector Laboratories, Burlingame, CA, USA) 370 
followed by a final SAPE staining step.  Fluorescent pixel intensities for each probe were 371 
determined using a confocal laser scanner (GeneArray Scanner, Affymetrix), processed, 372 
quantified, background adjusted and scaled using Affymetrix® Microarray Suite 5.0 373 
software. Further MAS 5.0 analysis of scaled intensity data generated the absolute 374 
analysis for each probe as well as comparative expression reading between two GeneChip 375 
arrays. Condition-to-condition differential expression profile analysis was carried out 376 
using Genomics Suite (Partek Incorporated, St.Louis, MO, USA). Principal component 377 
analysis was applied to identify any independent sources of variation in the data.  378 
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 379 
Pathway identification and visualization 380 
For comprehensive analysis of biological pathways in which transcripts were 381 
differentially expressed we combined expression data from the microarray analysis with 382 
information in Reactome version 29, (http://www.reactome.org), a knowledgebase of 383 
biological pathways (42). In order to visualize the networks we used MetaCore 384 
(http://genego.com) integrated knowledge database and software suite. Data analysis 385 
tools were used to generate high-resolution images of networks, with details of network 386 
objects and interactions provided in the Metacore legend (Appendix Figure 1). 387 
 388 
Western Blotting 389 
INS-1 cells were lysed and protein separated by SDS-PAGE. Protein was then transferred 390 
to nitrocellulose as described previously (39). Protein was detected using either anti-391 
STAT1 (Cell Signalling Technology, Beverly, Massachusetts, USA), anti-TNFR5 or anti-392 
NF-κB p65 primary antibody (both Santa Cruz Biotechnology, Dallas, USA), and Li-Cor 393 
IR secondary antibody (Lincoln, NE, USA).  Antibody binding was detected using the 394 
LI-COR Fc Dual-Mode Imaging System (LI-COR; Lincoln, USA).  395 
 396 
Immunofluoresence 397 
Cells were seeded in 12-well plates onto coverslips for 72h in different media conditions, 398 
then fixed in 4% paraformaldehyde in PBS for 30 minutes and subsequently washed 3 399 
times in PBS and store at +4°C overnight.  The following day, cells were permeabilized 400 
by with 0.1% Triton X-100 in PBS for 5 minutes, washed in 0.1% Triton in PBS, the 401 
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incubated in primary antibody for 2h at room temperature. Coverslips were then washed 402 
3 times in PBS + Triton X-100 and then incubated with secondary antibody conjugated to 403 
fluorescence dye (AF488) for 1h at room temperature. Images have been taken using a 404 
Leica DM5000 epi-fluo microscope. 405 
 406 
Gene Silencing 407 
INS-1 cells were cultured to 40-50% confluency. siRNA oligonucleotide was combined 408 
with diluted lipofectamine RNAi max and mixed gently. After 25 min at room temp the 409 
solution was mixed with RPMI and serum, but without antibiotics. This was then added 410 
to cells for 24h, after which it was replaced with complete RPMI. Knock-down was 411 
detected 48-72h after transfection by Western blot. 412 
 413 
NF-κB Activity 414 
TransAM NF-κB Family Kits (Active Motif, Rixensart, Belgium) were utilized for the 415 
study of specific NF-κB subunit pathways. Briefly, oligonucleotide containing an NF-κB 416 
consensus binding site was immobilized onto 96-well plates. The binding of NF-κB to its 417 
consensus sequence was detected by adding 30 μl of Complete Binding Buffer to each 418 
well and 1 μg of nuclear extract diluted in Complete Lysis Buffer was then added per 419 
well. The plates were sealed and incubated for 1 h at room temp with mild agitation. Each 420 
well was then washed 3X with 200 μl 1X Wash Buffer. Antibody directed against one of 421 
NF-κB p65 subunit was bound to the protein-oligonucleotide complex and detected 422 
following addition of secondary antibody, conjugated to horse radish peroxidase. 423 
Developing Solution was added and the plate was incubated for 2-10 min at room temp. 424 
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Absorbance was then measured, using a spectrophotometer (Perkin Elmer-Wallac, Milan, 425 
Italy) Victor-1420 multi-label counter at 450 nm with a reference wavelength of 655 nm. 426 
 427 
Statistical Analysis 428 
Results are expressed as mean ± SEM (n = 3 or more independent experiments).  429 
Parameters were compared using unpaired student t-test and a p-value of < 0.05 was 430 
considered significant. 431 
 432 
 433 
 434 
 435 
 436 
 437 
 438 
 439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
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ABBREVIATIONS 448 
Bcl-XL: B-cell lymphoma-extra large 449 
ER: endoplasmic reticulum 450 
HbA1C: haemoglobin A1C 451 
IFN: interferon 452 
IL: interleukin 453 
JAK: Janus kinase 454 
MAPK: mitogen activated protein kinase 455 
NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells 456 
NLRP: nucleotide-binding oligomerization domain receptor (NLR) family, pyrin domain 457 
containing 458 
PBS: phosphate buffered saline 459 
qRT-PCR: quantitative real time polymerase chain reaction 460 
ROS: reactive oxygen species 461 
RPMI: Roswell Park Memorial Institute 462 
sCD40L: soluble cluster of differentiation 40 ligand 463 
siRNA: short interfering ribonucleic acid 464 
STAT: signal transducer and activator of transcription 465 
T2D: type 2 diabetes 466 
TNFR: tumour necrosis factor receptor 467 
 468 
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TABLE LEGENDS 651 
 652 
Table 1 - Identification of associated diseases.  653 
INS-1 β-cells were incubated for 72h in RPMI-1640 media supplemented with or without 654 
28mM glucose, plus 200µM oleic acid, and 200µM palmitic acid. RNA was extracted 655 
and hybridized to Affymetrix® high density microarrays. Differentially expressed genes 656 
were determined using Partek® software, based on a p value  < 0.05 from three 657 
independent experiments. Predicted associated diseases were identified using MetaCore 658 
(http://genego.com) integrated knowledge database. 659 
 660 
Table 2 - TNFR family member expression.  661 
TNFR1, TNFR5, and TNFR6 expression was determined using Affymetrix array data and 662 
independent qRT-PCR analysis. Data is shown from three independent experiments. 663 
 664 
 665 
 666 
 667 
 668 
 669 
 670 
 671 
 672 
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FIGURE LEGENDS 674 
 675 
Figure 1 – Effect of glucolipotoxicity on β-cell ontology.  676 
Comparative analysis of gene expression from INS-1 cells incubated for 72h in RPMI-677 
1640 media supplemented with or without 28mM glucose, plus 200µM oleic acid, and 678 
200µM palmitic acid. Data is compiled from six independent microarray analyses (three 679 
per experimental group). Reactome pathway analysis (http://www.reactome.org) 680 
identified 13 significant biological functions / pathways (p < 0.05). 681 
 682 
Figure 2 - TNFR5 protein expression in INS-1 β-cells, high-fat fed mouse islets, and 683 
human islets.  684 
a) INS-1 cells incubated for 72h in RPMI-1640 media supplemented with or without 685 
28mM glucose, 200µM oleic acid, and 200µM palmitic acid. Immunoblots were 686 
conducted using anti-TNFR5 primary antibody (Santa Cruz Biotechnology, Dallas, USA) 687 
and Li-Cor IR secondary antibody (Lincoln, NE, USA), and are representative of three 688 
independent experiments. b) Imuunofluorescence of INS-1 cells fixed in 4% 689 
paraformaldehyde for 30 min, then permeabilized with 0.1% Triton X-100. Samples were 690 
treated with anti-DAPI (blue; Life Technologies Ltd., Paisley, UK) or anti-TNFR5 691 
primary antibody (green) and incubated with secondary antibody conjugated to 692 
fluorescence dye (AF488) (Life Technologies Ltd.). Images were taken with a Leica Epi-693 
fluo microscope using either a 20X objective (upper panels) or 40X objective (lower 694 
panels) and in each case are representative of three independent experiments. c) C57Bl/6 695 
mice were fed a high-fat or standard rodent diet for 10 weeks. Islets of mice were 696 
 29 
extracted and digested with collagenase, RNA extracted, reverse-transcribed and qRT-697 
PCR analysis performed. Data was analysed using the ΔΔCT method from four 698 
independent experiments. d) Human islets were cultured 24h with or without 0.5 mM 699 
palmitate. RNA was extracted, reverse-transcribed and qRT-PCR analysis performed. 700 
Data was analysed using the ΔΔCT method from six independent experiments. * p < 0.05 701 
 702 
Figure 3 - Network analysis of TNFR5 signalling.  703 
MetaCore (http://genego.com) was used to build a network from significantly up-704 
regulated genes in INS-1 cells subjected to glucolipotoxicity. The most significant 705 
biological network (p < 0.001) included positive regulation of cellular, biological, and 706 
metabolic processes linked to TNFR5 and JAK/STAT signaling. Details of network 707 
objects and interactions are provided in the Metacore legend (Appendix Figure 1). Thick 708 
cyan lines indicate the fragments of canonical pathways. Up-regulated genes are marked 709 
with red circles. 710 
 711 
Figure 4 – Effect of TNFR5 on STAT1 expression.  712 
a) INS-1 cells were either mock-transfected, transfected with scramble sequence RNA 713 
(ssRNA), or with specific interfering oligonucleotide (siRNA). Cells were then incubated 714 
for 72h in RPMI-1640 media supplemented with or without 28mM glucose, plus 200µM 715 
oleic acid, and 200µM palmitic acid. Immunoblots were conducted using anti-TNFR5 716 
primary antibody (Santa Cruz Biotechnology, Dallas, USA). Alpha-tubulin was used for 717 
normalization of the data. TNFR5 protein expression fold-changes are expressed as mean 718 
± SEM of data obtained from three different experiments. b) INS-1 cells were either 719 
 30 
mock-transfected, transfected with ssRNA, or with siRNA oligonucleotide. Cells were 720 
then incubated for 72h in RPMI-1640 media supplemented with or without 28mM 721 
glucose, plus 200µM oleic acid, and 200µM palmitic acid. Immunoblots were conducted 722 
using anti-STAT1 primary antibody (Cell Signalling Technology, Beverly, 723 
Massachusetts, USA). Alpha-tubulin was used for normalization of the data. Protein 724 
expression fold-changes are expressed as mean ± SEM from data obtained from three 725 
different experiments. * p < 0.05, ** p< 0.01, *** p< 0.001. 726 
 727 
Figure 5 - Effect of TNFR5 signalling on NF-κB expression, localization and activity.  728 
a)  INS-1 cells were incubated for 72h in RPMI-1640 media supplemented with or 729 
without 28mM glucose, plus 200µM oleic acid, and 200µM palmitic acid (GLT). 730 
Immunoblots were conducted using using anti-NF-κB p65 subunit primary antibody 731 
(Santa Cruz Biotechnology, Dallas, USA). Beta-actin was used for normalization of the 732 
data. Data presented is representative of three independent experiments. b) INS-1 cells 733 
were cultured onto coverslips and incubated with CD40 ligand (1 μg/ml) for 6h. Cells 734 
were then fixed and stained with anti-NF-κB p65 polycolonal antibody (green) and DAPI 735 
(blue). Images were taken with a Leica EpiFluo microscope with a 63x objective 736 
(representative image of three independent experiments). p65 translocation to the nucleus 737 
was quantified using Image J. c) INS-1 rat pancreatic β-cells were cultured in RPMI-738 
1640 media supplemented with glucose, TNF or CD40 at the indicated concentrations 739 
and for the duration stated. NF-κB subunit activity was detected using TransAm ELISA 740 
kit (Active Motif, Rixensart, Belgium) directed against NFκB p65 subunits. Absorbance 741 
was measured at 450nm, with a reference wavelength of 655nm. All experimental data 742 
 31 
were gathered from a series of three independent experiments. d) INS-1 cells were either 743 
mock-transfected, transfected with ssRNA, or with siRNA oligonucleotide, and cells then 744 
incubated for 72h in RPMI-1640 media. NF-kB activity was quantified as outlined above. 745 
Experimental data were gathered from a series of five independent experiments.  746 
* p < 0.05 747 
 748 
 749 
Appendix Table 1 750 
Significant differentially expressed genes in INS-1 β-cells following exposure to a 751 
glucolipotoxic environment using Partek ® software, based on a p value < 0.05 with a 752 
fold change greater or less than 2. 753 
 754 
Appendix Table 2 755 
Expression of interferon-associated genes was determined using Affymetrix array data 756 
and independent qRT-PCR analysis. Data is shown from three independent experiments. 757 
 758 
Appendix Figure 1 759 
Metacore (http://genego.com) integrated knowledge database legend describing details of 760 
network objects and interactions. 761 
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TABLE I 770 
 771 
 772 
ASSOCIATED DISEASES RATIO P VALUE 
Mental Disorders 206/1593 1.212E-13 
Psychiatry and Psychology 233/1875 1.810E-13 
Mood Disorders 121/789 3.601E-13 
Glioma 492/4765 6.519E-13 
Neoplasms, Neuroepithelial 511/4996 9.286E-13 
Breast Neoplasms 813/8688 3.199E-12 
Breast Diseases 813/8689 3.291E-12 
Neoplasms, Glandular and Epithelial 808/8659 8.177E-12 
Endocrine System Diseases 564/5714 2.006E-11 
Digestive System Neoplasms 1044/11780 1.513E-10 
Skin Diseases 993/11125 1.770E-10 
Rectal Diseases 823/8967 2.047E-10 
Gonadal Disorders 334/3128 2.920E-10 
Genital Diseases, Female 1129/12925 3.174E-10 
Pathological Process 290/2642 3.419E-10 
Astrocytoma 296/2709 3.514E-10 
Genital Neoplasms, Female 1119/12809 4.717E-10 
Gastrointestinal Neoplasms 940/10509 8.836E-10 
Ovarian Neoplasms 313/2927 1.068E-09 
Nutritional and Metabolic Diseases 328/3099 1.214E-09 
Ovarian Diseases 323/3046 1.370E-09 
Adnexal Diseases 323/3049 1.528E-09 
Glioblastoma 286/2636 1.565E-09 
Digestive System Diseases 1071/12231 1.672E-09 
Intestinal Neoplasms 839/9256 1.826E-09 
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TABLE II 775 
 776 
 777 
 TNFR1 TNFR5 TNFR6 
Affymetrix - 2.23  (p<0.0001) 1.59  (p<0.05) 
PCR 2.23  (p=ns) 3.62  (p<0.05) 1.19  (p=ns) 
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